This newsletter presents you the following key sessions:
1. Video-interview with Paul Germonpré
2. Adding capecitabine to maintenance bevacizumab delays progression and prolongs survival in women
with HER2-negative metastatic breast cancer
3. Phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS
analyses in untreated metastatic adenocarcinoma of the colon or rectum
4. No statistically significant improvement in progression-free survival from continued treatment with
gefitinib after the development of resistance
5. Adding cobimetinib to vemurafenib significantly prolongs progression-free survival in patients with
BRAFV600-mutant metastatic melanoma
6. Ramucirumab improves progression-free survival, time to progression and response rate without
prolonging overall survival in the second-line treatment of hepatocellular carcinoma